Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Teva Pharmaceutical Industries Limited has 1.17B shares outstanding.

As of June 30, 2026, Teva Pharmaceutical Industries Limited maintains a current ratio of 0.88, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 217.53, indicating elevated leverage, while an interest coverage ratio of 2.89 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited posted a return on equity (ROE) of 9.68, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 6.45 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 1.77, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.48, useful for judging operating efficiency across full business cycles. The company generates approximately 445,062.79 in revenue per employee across its workforce of 34,051.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.45 indicates how many times Teva Pharmaceutical Industries Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited recorded 10.50M in income tax expense. That works out to an effective tax rate of 1.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 619.71M, leaving 617.96M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited generated 15.15B in revenue and converted that into 617.96M in net income, yielding earnings per share of 0.53. EBITDA reached 2.27B, while operating income came in at 2.85B.

As of June 30, 2026, Teva Pharmaceutical Industries Limited holds 3.20B in cash and equivalents against 14.77B in total debt, resulting in a net debt position of 11.32B. Total book value stands at 6.79B, with working capital of -1.65B providing operational flexibility.

Teva Pharmaceutical Industries Limited produced 1.66B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -481.41M in capital expenditures, free cash flow totaled 1.18B - equivalent to 1.02 per share.

Over the twelve months ended June 30, 2026, Teva Pharmaceutical Industries Limited posted a gross margin of 52.45, reflecting its pricing power and cost economics. The operating margin of 18.78 and net profit margin of 4.08 provide insight into operational efficiency.

Teva Pharmaceutical Industries Limited's most recent stock split took place on June 27, 2004 with a 1:2 split ratio.